Celgene will be hosting a program on Thursday, December 10 from 1730-1930 regarding a treatment option for metastatic pancreatic cancer, non-small cell lung cancer, and metastatic breast cancer. Peter Bjerkerot, RN, OCN, BSN will be the featured speaker. The program … Continued
FDA granted approval to necitumumab (PORTRAZZA, Eli Lilly and Company) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of non-squamous NSCLC.